Tags

Type your tag names separated by a space and hit enter

KPC-53, a KPC-3 Variant of Clinical Origin Associated with Reduced Susceptibility to Ceftazidime-Avibactam.
Antimicrob Agents Chemother. 2020 12 16; 65(1)AA

Abstract

This study reports on the characterization of a Klebsiella pneumoniae clinical isolate showing high-level resistance to ceftazidime-avibactam associated with the production of KPC-53, a KPC-3 variant exhibiting a Leu167Glu168 duplication in the Ω-loop and a loss of carbapenemase activity. Whole-genome sequencing (WGS) revealed the presence of two copies of bla KPC-53, located on a pKpQIL-like plasmid and on a plasmid prophage of the Siphoviridae family, respectively. The present findings provide new insights into the mechanisms of resistance to ceftazidime-avibactam.

Authors+Show Affiliations

Department of Surgical Sciences and Integrated Diagnostics, University of Genoa, Genoa, Italy.Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.Clinical Microbiology and Virology Unit, A. Manzoni Hospital, Lecco, Italy.Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. Clinical Microbiology and Virology Unit, Florence Careggi University Hospital, Florence, Italy.Clinical Microbiology and Virology Unit, A. Manzoni Hospital, Lecco, Italy.Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. Clinical Microbiology and Virology Unit, Florence Careggi University Hospital, Florence, Italy.Clinical Microbiology and Virology Unit, A. Manzoni Hospital, Lecco, Italy.Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy gianmaria.rossolini@unifi.it. Clinical Microbiology and Virology Unit, Florence Careggi University Hospital, Florence, Italy.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

33106265

Citation

Di Pilato, Vincenzo, et al. "KPC-53, a KPC-3 Variant of Clinical Origin Associated With Reduced Susceptibility to Ceftazidime-Avibactam." Antimicrobial Agents and Chemotherapy, vol. 65, no. 1, 2020.
Di Pilato V, Aiezza N, Viaggi V, et al. KPC-53, a KPC-3 Variant of Clinical Origin Associated with Reduced Susceptibility to Ceftazidime-Avibactam. Antimicrob Agents Chemother. 2020;65(1).
Di Pilato, V., Aiezza, N., Viaggi, V., Antonelli, A., Principe, L., Giani, T., Luzzaro, F., & Rossolini, G. M. (2020). KPC-53, a KPC-3 Variant of Clinical Origin Associated with Reduced Susceptibility to Ceftazidime-Avibactam. Antimicrobial Agents and Chemotherapy, 65(1). https://doi.org/10.1128/AAC.01429-20
Di Pilato V, et al. KPC-53, a KPC-3 Variant of Clinical Origin Associated With Reduced Susceptibility to Ceftazidime-Avibactam. Antimicrob Agents Chemother. 2020 12 16;65(1) PubMed PMID: 33106265.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - KPC-53, a KPC-3 Variant of Clinical Origin Associated with Reduced Susceptibility to Ceftazidime-Avibactam. AU - Di Pilato,Vincenzo, AU - Aiezza,Noemi, AU - Viaggi,Valentina, AU - Antonelli,Alberto, AU - Principe,Luigi, AU - Giani,Tommaso, AU - Luzzaro,Francesco, AU - Rossolini,Gian Maria, Y1 - 2020/12/16/ PY - 2020/07/06/received PY - 2020/10/20/accepted PY - 2020/10/28/pubmed PY - 2020/10/28/medline PY - 2020/10/27/entrez KW - CZA resistance KW - carbapenem-resistant Enterobacterales KW - mutant KPC carbapenemase KW - phagemid JF - Antimicrobial agents and chemotherapy JO - Antimicrob Agents Chemother VL - 65 IS - 1 N2 - This study reports on the characterization of a Klebsiella pneumoniae clinical isolate showing high-level resistance to ceftazidime-avibactam associated with the production of KPC-53, a KPC-3 variant exhibiting a Leu167Glu168 duplication in the Ω-loop and a loss of carbapenemase activity. Whole-genome sequencing (WGS) revealed the presence of two copies of bla KPC-53, located on a pKpQIL-like plasmid and on a plasmid prophage of the Siphoviridae family, respectively. The present findings provide new insights into the mechanisms of resistance to ceftazidime-avibactam. SN - 1098-6596 UR - https://www.unboundmedicine.com/medline/citation/33106265/KPC_53_a_KPC_3_Variant_of_Clinical_Origin_Associated_with_Reduced_Susceptibility_to_Ceftazidime_Avibactam_ DB - PRIME DP - Unbound Medicine ER -